Open Nav

XOMA Corporation

  • Tom Burns, XOMA Corporation

Investor relations and business development

  • Date:Wednesday, October 17
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:XOMA has built a portfolio of over two dozen products that are licensed to and being developed by other biotech and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future. For more information, visit
  • Company
  • Company HQ City:Emeryville
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:$168 Million
  • Ticker:XOMA
  • Exchange:NASDAQ
  • CEO/Top Company Official:Jim Neal
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development :XOMA 213
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
Tom Burns
XOMA Corporation